ClearSight Validation in Pediatrics
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03701646 |
|
Recruitment Status : Unknown
Verified October 2018 by Nemours Children's Clinic.
Recruitment status was: Recruiting
First Posted : October 10, 2018
Last Update Posted : October 10, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Shock Hypotension and Shock | Device: Measurement by Clearsight device |
Specific aim number one: To compare cardiac output measurements obtained from the Clear Sight cardiac output monitor with measurements obtained with thermodilution in the cardiac catheterization laboratory. Significance: Currently, based on the Surviving Sepsis guidelines, fluid administration is supposed to be guided by measurements of fluid responsiveness. Currently, there very few ways to obtain measurements of fluid responsiveness, such as cardiac output, stroke volume, and systemic vascular resistance non-invasively. The invasive methods are no longer used in pediatrics, as the risk of placing these invasive catheters is felt to outweigh the benefit of using the data provided by the invasive cardiac output monitoring systems. Although the Clear Sight cardiac output monitoring system has been validated in adults to measure cardiac output non-invasively, this technology has not been evaluated in pediatrics. If the Clear Sight monitoring system is shown to be accurate in pediatrics, it would safely provide data that could be lifesaving to a pediatric patient in shock.
Specific aim number two: To compare the accuracy of the Clear Sight cardiac output monitor in obtaining continuous blood pressure measurements non-invasively. Significance: Currently, the only reliable method to continuously monitor blood pressure in critically ill patients is with an invasive intra-arterial catheter. Placing this catheter carries risks with it, including risk of infection as well as risk of intra-arterial thrombus which can lead to limb ischemia. The Clear Sight cardiac output monitor has the technology to obtain continuous blood pressure measurements non-invasively, although this technology has never been validated in pediatric patients. Therefore, specific aim 1 is to determine if this technology can reliably be used in pediatric patients. If it can, this would provide a method to obtain continuous blood pressure measurements without the risk of an invasive catheter.
Hypothesis: Cardiac output and arterial blood pressure measurements taken non-invasively with the ClearSight system in will correlate with cardiac output measurements taken by pulmonary artery catheter thermodilution and arterial blood pressure measurements taken by arterial line. This hypothesis is based on personal communications with the developers of this device.
| Study Type : | Observational |
| Estimated Enrollment : | 30 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Prospective |
| Official Title: | Comparing Non-invasive Cardiac Output Measurements by the ClearSight Hemodynamic Monitoring System to Thermodilution Measurements in Pediatric Patients Undergoing Cardiac Catheterization. |
| Actual Study Start Date : | November 2, 2017 |
| Estimated Primary Completion Date : | March 1, 2019 |
| Estimated Study Completion Date : | June 1, 2019 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
arterial line
Pediatric patients admitted tot he ICU with a medically indicated arterial line.
|
Device: Measurement by Clearsight device
Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements. |
|
cardiac output
Pediatric patients requiring cardiac output measurement by thermodilution through cardiac catheterization.
|
Device: Measurement by Clearsight device
Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements. |
- Measurement of non-invasive cardiac output or continuous blood pressure correlated to invasive measurements. [ Time Frame: 11/2/2017 - 6/1/2019 ]Comparison of measurements obtained by the ClearSight device compared to the invasive measurements will be used to evaluate whether the ClearSight device has any validity in pediatrics.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Arm 1) Cardiac output measurements Patients will be selected as potential study participants from the patients undergoing cardiac catheterization in the Nemours Cardiac Center for medically indicated reasons.
Patients selected should meet the following criteria:
- Age 17 years old or younger
- Receiving a cardiac catheterization, including cardiac output measurement, for clinical purposes, as determined by their cardiologist
- Hemodynamically stable with a scheduled non-emergent catheterization
Patients will be excluded from this study if:
- have digits too small to effectively fit into the smallest ClearSight finger probe
- Are hemodynamically unstable
Arm 2) Arterial blood pressure measurements
Patients will be selected as potential study participants from the patients admitted to the pediatric intensive care unit and now requiring an arterial line for medically indicated reasons.
Patients selected should meet the following criteria:
- Age 17 years old or younger
Patients will be excluded from this study if:
- Have digits too small to effectively fit into the smallest ClearSight finger probe
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03701646
| United States, Delaware | |
| Nemours A.I. duPont Hospital for Children | Recruiting |
| Wilmington, Delaware, United States, 19805 | |
| Contact: Hussam Alharash, MD 302-518-3566 hussam.alharash@nemours.org | |
| Responsible Party: | Nemours Children's Clinic |
| ClinicalTrials.gov Identifier: | NCT03701646 |
| Other Study ID Numbers: |
1146179 |
| First Posted: | October 10, 2018 Key Record Dates |
| Last Update Posted: | October 10, 2018 |
| Last Verified: | October 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Product Manufactured in and Exported from the U.S.: | No |
|
Hypotension Shock Pathologic Processes Vascular Diseases Cardiovascular Diseases |

